SCORPIO-HR Study
STUDY BASICS
If you have tested positive for Covid-19 in the last 3 days and are considered at standard risk for severe COVID-19 and have none of the risk factors that would put you at higher risk of disease progression you may be able to participate in a study to determine the safety and effectiveness of an experimental medication for COVID-19.
STUDY PURPOSE
The purpose of this study is to evaluate the ability of an experimental oral drug called S-217622 to improve the health of people with coronavirus disease 2019 (COVID-19). We also want to see if this study drug is safe, and if this study drug can shorten the time you have COVID-19 symptoms, reduce the amount of virus in the body, and prevent hospitalization or death. You will be eligible for this study if you are considered at lower risk for severe COVID-19 and have none of the risk factors that would put you at higher risk of disease progression.
WHAT PARTICIPANTS CAN EXPECT
If you are in this study, the following study procedures are required:
- You will record your symptoms
- You will provide blood samples
- You will have nasopharyngeal swabs (deep nasal swabs), and swabs of the front of the nose (anterior nasal swabs) collected by study staff
IRB: STUDY22010170
- ACTIV-2d/A5407MEET THE RESEARCHER

Madhu Choudhary
Madhu Choudhary is an Associate Professor in the Division of Infectious Diseases in the Department of Medicine at the University of Pittsburgh. A graduate of Maulana Azad Medical College, Dr. Choudhary’s research interests include HIV and viral hepatitis therapeutic clinical trials.